Upside case
Bull case
—
The bull case requires both strong earnings delivery and the market pricing MOVE more generously than it does today.
Analysis OverviewBuyUpdated Jun 18, 2026
Corvex, Inc. (MOVE) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
4
analysts
2 bullish · 0 bearish · 4 covering MOVE
Strong Buy
0
Buy
2
Hold
2
Sell
0
Strong Sell
0
Consensus Target
—
— vs today
Scenario Range
— – —
Model bear to bull value window
Coverage
4
Published analyst ratings
Valuation Context
—
Forward P/E · Market cap $36.7B
MOVE price targets
Three scenarios for where MOVE stock could go
Current
~$23
Confidence
46 / 100
Updated
Jun 18, 2026
Market caseClosest to today
Base case
—
The base case reflects analyst consensus expectations — steady delivery without requiring a major catalyst or re-rating.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Corvex, Inc.
MOVE · NASDAQHealthcareMedical - DevicesDecember year-end
Movano develops wearable health monitoring devices — primarily the Movano Ring — that track vital signs like heart rate, sleep, and blood oxygen. The company generates revenue from direct-to-consumer sales of its smart rings and plans to monetize subscription services for health insights and data analytics. Its competitive advantage lies in proprietary radiofrequency sensor technology that enables medical-grade monitoring in a compact, consumer-friendly form factor.
Market Cap
$36.7B
Revenue TTM
$737000
Net Income TTM
-$18M
Net Margin
-2470.6%
MOVE Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
25%Exceptional
12 quarters tracked
Revenue Beat Rate
0%Mixed
vs consensus estimates
Avg EPS Surprise
-1338.7%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q1 2026
Q1 2026
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 1 of 4Q1 2026
EPS
$-15.92/$-6.70
Revenue
$44000/$5M
Q1 2026
EPS
$-5.88/$-2.65
Revenue
—/$8M
Q1 2026
EPS
$-4.77/$-4.93
Revenue
$44000/$5M
Q2 2026
EPS
$-3.13/$-2.65
Revenue
$510000/$8M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q1 2026 | $-15.92/$-6.70 | -137.6% | $44000/$5M | -99.1% |
| Q1 2026 | $-5.88/$-2.65 | -121.8% | —/$8M | — |
| Q1 2026 | $-4.77/$-4.93 | +3.3% | $44000/$5M | -99.1% |
| Q2 2026 | $-3.13/$-2.65 | -18.1% | $510000/$8M | -93.3% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$744370
+1.0% YoY
FY2
$768572
+3.3% YoY
EPS Outlook
FY1
$-0.00
+99.1% YoY
FY2
$-0.00
— YoY
Trailing FCF (TTM)-$17M
FCF Margin: -2373.3%
Next Earnings
August 13, 2026
Expected EPS
$-3.17
Expected Revenue
$7M
MOVE beat EPS estimates in 1 of 4 tracked quarters. Mixed delivery makes the upcoming report a key data point for re-rating.
MOVE Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Relative Valuation
Benchmark comparison across market, sector, and history below.
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
MOVE
-83.4x
vs
S&P 500
24.4x
441% discount
vs Healthcare Trailing P/E
MOVE
-83.4x
vs
Healthcare
22.1x
477% discount
vs MOVE 5Y Avg P/E
Today
-83.4x
vs
5Y Average
—
Benchmark unavailable
Forward PE
—
S&P 500
18.8x
—
Healthcare
18.3x
—
5Y Avg
—
—
Trailing PE
-83.4x
S&P 500
24.4x
-441%
Healthcare
22.1x
-477%
5Y Avg
—
—
PEG Ratio
—
S&P 500
1.66x
—
Healthcare
1.59x
—
5Y Avg
—
—
EV/EBITDA
—
S&P 500
15.2x
—
Healthcare
14.2x
—
5Y Avg
—
—
Price/FCF
—
S&P 500
20.7x
—
Healthcare
18.5x
—
5Y Avg
—
—
Price/Sales
9999.0x
S&P 500
3.1x
+323304%
Healthcare
2.6x
+379261%
5Y Avg
—
—
Dividend Yield
—
S&P 500
1.91%
—
Healthcare
1.50%
—
5Y Avg
—
—
| Metric | MOVE | S&P 500 | Healthcare | 5Y Avg MOVE |
|---|---|---|---|---|
| Forward PE | — | 18.8x | 18.3x | — |
| Trailing PE | -83.4x | 24.4x-441% | 22.1x-477% | — |
| PEG Ratio | — | 1.66x | 1.59x | — |
| EV/EBITDA | — | 15.2x | 14.2x | — |
| Price/FCF | — | 20.7x | 18.5x | — |
| Price/Sales | 9999.0x | 3.1x+323304% | 2.6x+379261% | — |
| Dividend Yield | — | 1.91% | 1.50% | — |
MOVE trades above S&P 500 benchmarks on 1 of 2 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolMOVE Financial Health
Verdict
Stressed
Key financial metrics for MOVE are shown below.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$737000
Revenue Growth
TTM vs prior year
+100.8%
Gross Margin
Gross profit as a share of revenue
-190.8%
Operating Margin
Operating income divided by revenue
-2050.5%
Net Margin
Net income divided by revenue
-2470.6%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$-0.01
Free Cash Flow (TTM)
Cash generation after capex
-$17M
FCF Margin
FCF as share of revenue — the primary cash quality signal
-2373.3%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
—
ROA
Return on assets, trailing twelve months
-11.7%
Cash & Equivalents
Liquid assets on the balance sheet
$3M
Net Debt
Total debt minus cash
$2M
Debt Serviceability
Net debt as a multiple of annual free cash flow
—
ROE
Return on equity, trailing twelve months
-12.7%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.0%
Dividend
—
Buyback
0.0%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$0
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Current diluted share count
1.6B
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageMOVE Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
High Risk
Execution Risks
Integration challenges post-merger and competition from hyperscalers pose significant risks to Corvex's strategy.
High Risk
Capital Needs
Substantial capital requirements for GPU scaling could strain financial resources and impact growth.
Medium
Strategic Shift
Transition from health wearables to AI cloud computing introduces uncertainty and execution risk.
Medium
Competitive Pressure
Intense competition in the AI cloud space may limit market share and profitability.
Lower
Market Sentiment
High-risk perception of the stock could lead to volatility and investor skepticism.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why MOVE Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Strategic AI focus
Corvex Inc (MOVE) is strategically focusing on AI infrastructure and confidential computing, positioning itself for future growth in these high-potential areas.
Leadership transformation
The appointment of Jim Barber, former UPS COO, as CEO in June 2025 signals a strong leadership shift aimed at driving operational and financial improvements.
Cost savings target
The company has a clear transformation plan targeting at least USD 75M of annual cost savings by the end of fiscal 2026, which could significantly improve profitability.
Public company transparency
Corvex, Inc. maintains robust public-company filings, including material-event reporting and governance disclosures, enhancing investor confidence and transparency.
Market visibility
Corvex, Inc. (MOVE) is actively covered by financial news and market data platforms, providing visibility and accessibility to investors.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
MOVE Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$22.53
52W Range Position
59%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$4.67
+382.4% from the low
52-Week High
$34.87
-35.4% from the high
1 Month
+22.18%
3 Month
+49.30%
YTD
+156.6%
1 Year
+192.6%
3Y CAGR
-47.5%
5Y CAGR
-50.0%
10Y CAGR
-31.5%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
MOVE vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
—
vs 24.3x median
Peer median unavailable
Revenue Growth
+1.0%
vs +10.2% median
-90% below peer median
Net Margin
-2470.6%
vs 17.6% median
-14101% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
MOV MOVE Corvex, Inc. | $36.7B | — | +1.0% | -2470.6% | Buy | — |
MNM MNMD Mind Medicine (MindMed) Inc. | $2.0B | — | — | — | Buy | -3.3% |
AEY AEYE AudioEye, Inc. | $79M | — | +11.6% | -9.0% | — | — |
BWA BWAY BrainsWay Ltd. | $584M | 49.1x | +12.7% | 15.7% | Buy | +7.5% |
GRM GRMN Garmin Ltd. | $45.2B | 24.3x | +8.7% | 23.3% | Hold | +15.6% |
FIT FITB Fifth Third Bancorp | $35.3B | 17.2x | +1.5% | 19.6% | Buy | +9.0% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
FAQ
6 questionsMOVE Investor Questions
Common questions answered from live analyst data and company financials.
01Is Corvex, Inc. (MOVE) stock a buy or sell in 2026?
Corvex, Inc. (MOVE) is rated Buy by Wall Street analysts as of 2026. Of 4 analysts covering the stock, 2 rate it Buy or Strong Buy, 2 rate it Hold, and 0 rate it Sell or Strong Sell.
02Is Corvex, Inc. (MOVE) stock overvalued in 2026?
Forward earnings data for MOVE is not currently available. Review the valuation table above for trailing P/E, EV/EBITDA, and price-to-sales comparisons against market and sector benchmarks.
03What are the main risks for Corvex, Inc. (MOVE) stock in 2026?
The primary risks for MOVE in 2026 are: (1) Execution Risks — Integration challenges post-merger and competition from hyperscalers pose significant risks to Corvex's strategy. (2) Capital Needs — Substantial capital requirements for GPU scaling could strain financial resources and impact growth. (3) Strategic Shift — Transition from health wearables to AI cloud computing introduces uncertainty and execution risk. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
04What is Corvex, Inc.'s revenue and earnings forecast?
Analyst consensus estimates MOVE will report consensus revenue of $744370 (+1.0% year-over-year) and EPS of $-0.00 (+99.1% year-over-year) for the upcoming fiscal year. The following year, analysts project $768572 in revenue.
05When does Corvex, Inc. (MOVE) report its next earnings?
Corvex, Inc. is expected to report its next earnings on approximately 2026-08-13. Consensus expects EPS of $-3.17 and revenue of $7M. Over recent quarters, MOVE has beaten EPS estimates 25% of the time.
06How much free cash flow does Corvex, Inc. generate?
Corvex, Inc. (MOVE) had a free cash outflow of $17M in free cash flow over the trailing twelve months — a free cash flow margin of 2373.3%. MOVE returns capital to shareholders through and share repurchases ($0 TTM).